CGTX
CGTX clinical trials: COGNITION THERAPEUTICS INC
Every trial on ClinicalTrials.gov where COGNITION THERAPEUTICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CGTX on the catalyst calendar · CGTX registry changes
- Primary completion May 31, 2027Sponsor estimatePhase 2NCT05531656A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseCognition Therapeutics · Early Alzheimer's DiseaseActive, not recruitingCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06961760Expanded Access Program for CT1812 (Zervimesine)Cognition Therapeutics · Dementia With Lewy BodiesNo longer availableCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 25, 2024ActualPhase 2NCT05225415Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesCognition Therapeutics · Dementia With Lewy BodiesCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2024ActualPhase 2NCT03507790A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.Cognition Therapeutics · Mild to Moderate Alzheimer's DiseaseCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2025ActualPhase 2NCT05893537Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related...Cognition Therapeutics · Age-Related Macular DegenerationTerminatedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2023ActualPhase 2NCT04735536Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGCognition Therapeutics · Alzheimer DiseaseCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2020ActualPhase 1/Phase 2NCT03493282Effect of CT1812 Treatment on Brain Synaptic DensityCognition Therapeutics · Alzheimer DiseaseCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2022ActualPhase 1NCT05225389Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male SubjectsCognition Therapeutics · Alzheimer DiseaseCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2022ActualPhase 1NCT05248672Study to Assess the Pharmacokinetics of CT1812 in Older Healthy VolunteersCognition Therapeutics · Alzheimer DiseaseCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 6, 2019ActualPhase 1NCT03522129Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate...Cognition Therapeutics · Alzheimer DiseaseCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2016ActualPhase 1NCT03716427Drug Interaction Study of CT1812 in Healthy VolunteersCognition Therapeutics · Healthy VolunteersCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 24, 2017ActualPhase 1/Phase 2NCT02907567Clinical Trial of CT1812 in Mild to Moderate Alzheimer's DiseaseCognition Therapeutics · Alzheimer's DiseaseCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualPhase 1NCT02570997Ascending Dose Study of CT1812 in Healthy VolunteersCognition Therapeutics · Cognitive ImpairmentCompletedCGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner